Roughly one week after announcing that it was undertaking a review of strategic alternatives, life sciences company Avivagen, which manufactures the OxC-beta product for livestock, has experienced a lift thanks to an existing customer.
The company issued an announcement confirming that an existing customer has placed an order sized at 400 per cent of its normal monthly order volume, up to 400 kilograms from 100 kilograms. The company says this demonstrates an increase in demand and traction for OxC-beta in the customer’s region of Southeast Asia.
“We have seen a number of our customers increase their orders as they become more familiar with Avivagen’s product, its cases and utility,” said CEO Kym Anthony in a statement. Anthony added that the company believes this model “can be replicated around the world.” Anthony confirmed that the company’s strategic review process is ongoing.
Print this page
